- Home
- IBP vs LEGN Comparison
IBP vs LEGN Comparison
Compare IBP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBP | LEGN |
|---|---|---|
| Founded | 1977 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IBP | LEGN |
|---|---|---|
| Price | $260.68 | $17.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $278.57 | $63.08 |
| AVG Volume (30 Days) | 289.8K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 6.70 | N/A |
| EPS | ★ 9.71 | N/A |
| Revenue | ★ $2,970,800,000.00 | N/A |
| Revenue This Year | $2.09 | $43.65 |
| Revenue Next Year | $4.32 | $32.75 |
| P/E Ratio | $27.58 | ★ N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $150.83 | $16.24 |
| 52 Week High | $349.00 | $45.30 |
Technical Indicators
Market Signals| Indicator | IBP | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 46.14 |
| Support Level | $254.38 | $17.46 |
| Resistance Level | $277.05 | $20.39 |
| Average True Range (ATR) | 11.26 | 0.75 |
| MACD | 0.73 | 0.11 |
| Stochastic Oscillator | 28.43 | 40.98 |
Price Performance
Historical ComparisonAbout IBP Installed Building Products Inc.
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.